Recro Pharma Inc (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 100,000 shares of the firm’s stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $10.00, for a total transaction of $1,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Tuesday, November 28th, Healthcare Master Fun Broadfin sold 47,549 shares of Recro Pharma stock. The shares were sold at an average price of $9.64, for a total transaction of $458,372.36.
  • On Thursday, November 30th, Healthcare Master Fun Broadfin sold 222,616 shares of Recro Pharma stock. The shares were sold at an average price of $9.58, for a total transaction of $2,132,661.28.
  • On Tuesday, November 21st, Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock. The stock was sold at an average price of $9.50, for a total transaction of $973,180.00.
  • On Friday, November 24th, Healthcare Master Fun Broadfin sold 172,208 shares of Recro Pharma stock. The stock was sold at an average price of $9.45, for a total transaction of $1,627,365.60.

Shares of Recro Pharma Inc (NASDAQ:REPH) traded up $0.19 on Thursday, hitting $9.52. 129,700 shares of the stock were exchanged, compared to its average volume of 120,931. Recro Pharma Inc has a 1 year low of $5.81 and a 1 year high of $10.59. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50.

Several research firms have commented on REPH. Zacks Investment Research lowered shares of Recro Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a research note on Friday, October 27th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Recro Pharma has a consensus rating of “Buy” and an average target price of $11.65.

Several institutional investors and hedge funds have recently modified their holdings of REPH. Janney Montgomery Scott LLC boosted its stake in shares of Recro Pharma by 76.9% during the second quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock valued at $155,000 after purchasing an additional 9,600 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Recro Pharma during the first quarter valued at $156,000. Teachers Advisors LLC purchased a new stake in shares of Recro Pharma during the second quarter valued at $162,000. California State Teachers Retirement System purchased a new stake in shares of Recro Pharma during the second quarter valued at $169,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Recro Pharma by 183.4% during the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after purchasing an additional 14,098 shares during the period. 61.55% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/07/healthcare-master-fun-broadfin-sells-100000-shares-of-recro-pharma-inc-reph-stock.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.